Pluri Inc. (TLV: PLUR)

Market Cap	102.48M
Revenue (ttm)	2.22M
Net Income (ttm)	-81.07M
Shares Out	n/a
EPS (ttm)	-15.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	909
Open	1,984.00
Previous Close	1,984.00
Day's Range	1,940.00 - 1,984.00
52-Week Range	1,607.00 - 2,900.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Pluri

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 118
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: PLUR

Financial Performance

In 2024, Pluri's revenue was $326,000, an increase of 13.59% compared to the previous year's $287,000. Losses were -$20.89 million, -26.25% less than in 2023.

Financial numbers in USD